Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Truist Financial Issues Pessimistic Forecast for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price

Summary by marketbeat.com
Truist Financial reduced their price objective on shares of Regeneron Pharmaceuticals from $796.00 to $778.00 and set a "buy" rating on the stock in a research note on Monday.

1 Articles

marketbeat.commarketbeat.com
Center

Truist Financial Issues Pessimistic Forecast for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price

Truist Financial reduced their price objective on shares of Regeneron Pharmaceuticals from $796.00 to $778.00 and set a "buy" rating on the stock in a research note on Monday.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

marketbeat.com broke the news on Monday, May 18, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

Stock Markets icon

Stock Markets

Charlotte, North Carolina icon

Charlotte, North Carolina

Business & Markets icon

Business & Markets

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal